Management of ulcerative colitis and Crohn's disease

Acta Clinica Belgica

Volumn 59, Issue 5, 2004, Pages 304-314

  Baert, F ^a   Vermeire, S ^a   Noman, M ^a   Van Assche, G ^a   D'Haens, G ^a   Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biologicals; Crohn's disease; Medical management; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; GLUCOCORTICOID; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 11; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; ONERCEPT; SULFALAZINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ALLERGIC PNEUMONITIS; BIRTH DEFECT; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COUGHING; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DYSPNEA; FEVER; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOMODULATION; LEUKOPENIA; LIVER FIBROSIS; MOLECULAR BIOLOGY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; PARESTHESIA; PATHOGENESIS; PHOCOMELIA; PNEUMOCYSTOSIS; RASH; RELAPSE; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT WITHDRAWAL; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 11144291378     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2004.045     Document Type: Review

References (76)

1. Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 1994; 39: 1885-92.
2. Kozarck RA. Review article: immunosuppresive therapy for inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 117-23.
3. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety 1991; 6: 192-219.
4. Clemett D, Markham A. Prolonged -release mesalazine : a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 2000;59:929-56.
5. Corrigan G, Stevens PE. Interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Therap 2000;14:1-6.
6. Lochs H, Mayer M, Fleig WE et al. and the European Cooperative Crohn's Disease Study Group VI Group. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's disease study VI. Gastroenterology 2000;118:264-73.
7. Sutherland LR. Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there ? Gastroenterology 2000;118:436-8.
8. Cottone M, Cammà C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 2000;119:597.
9. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Ther 2000;14:145-53.
10. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease : benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
11. Kim PS, Zlatanic J, Koretlitz BI, Gleim GW. Optimum duration of treatment with 6 mercaptopurine for Crohn's disease. Am J Gastroenterology 1999;94:3254-57.
12. Feagan BG, Fedorak RN, Irvine J, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JWD. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000;342:1627-32.
13. Brynskov J, Freund L, Rasmussen SN. Final report on a placebo-controlled, double-blind, randomized trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991; 26: 689-95.
14. Feagan BG, McDonald JWD, Rochon J et al. Low-dose cyclosporin for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
15. Jewell DP, Lennard-Jones JE. and the cyclosporin study group of Great-Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499-505.
16. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR and the European Study Group. European trial of cyclosporin in chronic active Crohn's disease: a 12 month study. Gastroenterology 1995; 109: 774-82.
17. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1273-81.
18. Fellermann K, Tanko Z, Herrlinger KR et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8:317-24.
19. Lowry PW, Weaver AL, Tremaine WJ et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999; 5:239-45.
20. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997; 92:876-9.
21. Skelly MM, Logan RF, Jenkins D et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2002; 8:93-7.
22. Ford AC, Towler RJ, Moayyedi P et al. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 17:1365-9.
23. Hassard PV, Vasiliauskas EA, Kam LY et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis. 2000;6:16-20.
24. Fellermann K, Steffen M, Stein J et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14: 171-6.
25. Neurath MF, Wanitschke R, Peters M et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut. 1999; 44:625-8.
26. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucorticosteroid resistance and dependency in Crohn's disease. Gut 1994; 35(3): 360-2.
27. Lofberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996; 39(1): 82-6.
28. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337:1029-35
29. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340: 1398-405
30. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and Safety of Retreatment With Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease. Gastroenterology 1999;117:761-9
31. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet. 2002;359:1541-9.
32. D'haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999;116:1029-34.
33. Su C, Salzberg BA, Lewis JD et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577-84.
34. Kohn A, Prantera C, Pera A et al. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002;34:626-30.
35. Kaser A, Mairinger T, Vogel W et al. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001; 113:930-3.
36. Chey WY, Hussain A, Ryan C et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373-81.
37. Gornet JM, Couve S, Hassani Z et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003 15;18:175-81
38. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001; 7:83-8.
39. Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52:998-1002.
40. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521-624.
41. Sandborn WJ, Feagan BG, Hanauer SB et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-8.
42. Sandborn WJ, Feagan B, Radford-Smith G et al. A randomised placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF- in patients with moderate to severe Crohn's disease. Gastroenterol Suppl 2003; A469
43. Hanauer S, Present D, Targan SR et al. CDP571, a humanized monoclonal antibody to TNF-, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab. Gastroenterol Suppl 2003; T1357
44. Evans RC, Clarke L, Heath P et al. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP5T1. Aliment Pharmacol Ther. 1997; 11:1031-5.
45. McIntosh DG, Lukas M, Sandborn W et al. A randomised double blind placebo controlled trial of the clinical assessment of adalimumab safety and efficacy studied as an induction therapy. Gut 2204;53suppl 6 A47.
46. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
47. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002;50:196-200.
48. Waters MF, Laing AB, Ambikapathy A et al. Treatment of ulcerative colitis with thalidomide. Br Med J. 1979;1:792.
49. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999;117:1271-7.
50. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999;117:1278-87.
51. Sabate JM, Villarejo J, Lemann M et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther. 2002;16:1117-24.
52. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002;122:7-14.
53. Vermeire S, Noman M, Van Assche G et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-9.
54. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
55. Fedorak RN, Gangl A, Elson CO et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-1482.
56. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-1472.
57. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113:383-389.
58. Tilg H, van Montfrans C, van den Ende A et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002;50:191-195.
59. Colombel JF, Rutgeerts P, Malchow H et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut. 2001;49:42-46.
60. Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.
61. Lindsay JO, Ciesielski CJ, Scheinin T et al. The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol. 2001;166:7625-33.
62. Van Montfrans C, Rodriguez Pena MS, Pronk I et al. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002;123:1865-1876.
63. Sands BE, Bank S, Sninsky CA et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999;117:58-64.
64. Sands BE, Winston BD, Salzberg B et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther. 2002;16:399-406.
65. Burns RC, Rivera-Nieves J, Moskaluk CA et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology. 2001;121:1428-1436.
66. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114:1133-1142.
67. Schreiber S, Nikolaus S, Malchow H et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology. 2001;120:1339-1346.
68. Yacyshyn BR, Chey WY, Goff J et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51:30-36.
69. Gordon FH, Lai CW, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-74.
70. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
71. Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab. a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16:699-705.
72. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, Mc Kinley MJ. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000;342:1633-1637.
73. Dejaco C, Gasche C, Poetzi R, Gnagi A, Vogelsang H, Reinisch W. Safety and efficacy of granulocyte colony stimulating factor (G-CSF) for treatment of severe postoperative recurrence in Crohn's disease. Gastroenterology 2000;118:A566.
74. Dignass A, Targan S, Salzberg B et al. Visilizumab, a humanized anti CD3 monoclonal antibody is active in the treatment of severe steroid refractory ulcerative colitis study: preliminary results of a pahse I-II study. Gut 2004;53suppl VI:A54.
75. Gionchetti P, Rizzello F, Venturi A, Brigid P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis : a double blind, placebo controlled trial. Gastroenterology 2000;119:305-309.
76. Sartor B. Probiotics in chronic pouchitis : restoring luminal microbial balance. Gastroenterology 2000;119:584-586.